Thomas Reilly - Opthea Chief Officer
| OPT Stock | USD 3.17 0.01 0.32% |
Executive
Thomas Reilly is Chief Officer of Opthea
| Age | 52 |
| Address | 650 Chapel Street, South Yarra, VIC, Australia, 3141 |
| Phone | 61 3 9826 0399 |
| Web | https://opthea.com |
Thomas Reilly Latest Insider Activity
Tracking and analyzing the buying and selling activities of Thomas Reilly against Opthea stock is an integral part of due diligence when investing in Opthea. Thomas Reilly insider activity provides valuable insight into whether Opthea is net buyers or sellers over its current business cycle. Note, Opthea insiders must abide by specific rules, including filing SEC forms every time they buy or sell Opthea'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Thomas Reilly over three months ago Disposition of 16667 shares by Thomas Reilly of Amarin PLC subject to Rule 16b-3 | ||
Thomas Reilly over three months ago Disposition of 33333 shares by Thomas Reilly of Amarin PLC subject to Rule 16b-3 |
Opthea Management Efficiency
The company has Return on Asset of (0.8343) % which means that on every $100 spent on assets, it lost $0.8343. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (33.8308) %, meaning that it generated no profit with money invested by stockholders. Opthea's management efficiency ratios could be used to measure how well Opthea manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.22 in 2024. Return On Capital Employed is likely to gain to -1.46 in 2024. At this time, Opthea's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 198.2 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 39.8 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sanjeev Khindri | Aerovate Therapeutics | N/A | |
| Jeffrey Jensen | Inhibrx | N/A | |
| MD MBA | Molecular Partners AG | N/A | |
| MS MBA | Rezolute | 50 | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| Dr MBA | Acrivon Therapeutics, Common | N/A | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Michael Covarrubias | Rezolute | N/A | |
| Carlos Bais | Inhibrx | N/A | |
| Daron Evans | Rezolute | 50 | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| Charbel PharmD | Inhibrx | N/A | |
| Brendan Eckelman | Inhibrx | 45 | |
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| Xiaohong She | Adagene | 57 | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Gopal MBBS | Rezolute | N/A | |
| Marianna Zipeto | Champions Oncology | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
Management Performance
| Return On Equity | -33.83 | ||||
| Return On Asset | -0.83 |
Opthea Leadership Team
Elected by the shareholders, the Opthea's board of directors comprises two types of representatives: Opthea inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opthea. The board's role is to monitor Opthea's management team and ensure that shareholders' interests are well served. Opthea's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opthea's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| MD MA, Chief Advisor | ||
| Sarika Gulhar, Executive Resources | ||
| Michael Gerometta, Manufacturing Chemistry | ||
| Peter MBA, Chief Officer | ||
| Jen Watts, VP Operations | ||
| Karen CPA, VP Secretary | ||
| Anand Sundaram, Vice Marketing | ||
| PharmD MS, Chief Officer | ||
| Kenneth Sall, Chief Officer | ||
| Dayong Li, Biometrics VP | ||
| Mike Campbell, Chief Officer | ||
| Ian Leitch, Director Research | ||
| James Goding, Independent Consultant | ||
| Kevin Bitter, VP Development | ||
| MAICD MAICD, CEO MD | ||
| MSc BPHARM, Senior Operations | ||
| MD MBA, Chief Officer | ||
| Daniel MBA, Interim CFO | ||
| MS MD, Senior Development | ||
| Annie Lee, F Mang | ||
| Thomas Reilly, Chief Officer | ||
| Fang Li, Senior Affairs |
Opthea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opthea a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -33.83 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | 454 M | ||||
| Shares Outstanding | 153.89 M | ||||
| Shares Owned By Institutions | 3.57 % | ||||
| Number Of Shares Shorted | 73.55 K | ||||
| Price To Book | 4.31 X | ||||
| Price To Sales | 1,857 X | ||||
| Revenue | 261.86 K | ||||
| Gross Profit | 218.45 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Opthea Stock Analysis
When running Opthea's price analysis, check to measure Opthea's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opthea is operating at the current time. Most of Opthea's value examination focuses on studying past and present price action to predict the probability of Opthea's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opthea's price. Additionally, you may evaluate how the addition of Opthea to your portfolios can decrease your overall portfolio volatility.